The possibility of predicting effectiveness oftherapy in patients with new infiltrative pulmonary tuberculosis by baseline activity of adenosine deaminase and inflammatory response parameters
https://doi.org/10.21292/2075-1230-2022-100-5-28-34
Abstract
The objective: to evaluate the possibility of using the baseline activity of adenosine deaminase (ADA) to predict effectiveness of therapy in patients with new infiltrative pulmonary tuberculosis (IPTB).
Subjects and Methods. Data of 121 patients with new infiltrative pulmonary tuberculosis were analyzed; patients were divided into groups according to therapy effectiveness.
Results., The discriminant analysis of data of new infiltrative pulmonary tuberculosis patients made it possible to obtain adiscriminant function which included the activity of ADA, the concentration of haptoglobin (HP) and ceruloplasmin (CP) – parameters reflecting that severity of the disease and protective potential of the host.
Conclusion. Analysis of ADA activity in combination with level of HP and CP allows the following: predicting effectiveness of the intensive phase of therapy before it begins in patients with new infiltrative pulmonary tuberculosis (with the accuracy of 77.0%); assuming that the reduction of ADA activity and inhibition of the inflammatory response may be useful for treatment of patients with new infiltrative pulmonary tuberculosis.
About the Authors
M. E. Dyakova
St. Petersburg Research Institute of Phthisiopulmonology
Russian Federation
Russian Federation
Marina E. Dyakova, Candidate of Biological Sciences, Senior Researcher
32, Polytechnicheskaya St., St. Petersburg, 194064
Phone: +7 (812) 297-86-03
N. P. Аlekseeva
St. Petersburg Research Institute of Phthisiopulmonology; Pavlov First Saint Petersburg State Medical University; St. Petersburg University
Russian Federation
Russian Federation
Nina P. Аlekseeva, Candidate of Physical and Mathematical Sciences, Scientific Consultant
St. Petersburg
D. S. Esmedlyaeva
St. Petersburg Research Institute of Phthisiopulmonology
Russian Federation
Russian Federation
Dilyara S. Esmedlyaeva, Candidate of Biological Sciences, Senior Researcher
St. Petersburg
P. K. Yablonskiy
St. Petersburg Research Institute of Phthisiopulmonology; St. Petersburg University
Russian Federation
Russian Federation
Petr K. Yablonskiy, Doctor of Medical Sciences, Professor, Director
St. Petersburg
Phone: +7 (812) 579-25-54
References
1. Biokhemicheskiye metody issledovaniya v klinike. [Biochemistry techniques inthe clinic]. A.A. Pokrovsky, eds., Moscow, Meditsina Publ., 1969, 652 p.
2. Veremenko K.N. Proteoliz v norme i pri patologii. [Proteolysis in health and pathology]. Kiev, Zdorovye Publ., 1988, 200 p.
3. Dyakova M.E., Zhuravlev V.Yu., Torkatyuk E.А., Esmedlyaeva D.S., Perova T.L. Adenosine deaminase in the pathogenesis of infiltrative pulmonary tuberculosis and pneumonia. Meditsinsky Alyans, 2015, no. 4, pp. 60-67. (In Russ.)
4. Titarenko O.T., Dyakova M.E., Manicheva O.А., Esmedlyaeva D.S., Dogonadze M.Z., Аlekseeva N.P., Perova T.L. Biological properties of Mycobacterium tuberculosis and characteristics of the inflammatory response in infiltrative pulmonary tuberculosis. Infektsiya I Immunitet, 2014, vol. 4, no. 3, pp. 221-228. (In Russ.)
5. Titarenko O.T., Dyakova M.E., Pavlova M.V., Esmedlyaeva D.S., Аlekseeva N.P., Perova T.L. Clinical and laboratory comparisons in assessing the prognosis of treatment of patients with infiltrative pulmonary tuberculosis. Klinicheskaya Laboratornaya Diagnostika, 2012, no. 5, pp. 31-34. (In Russ.)
6. Titarenko O.T., Soldatova N.V., Umarov А.M., Perova T.L. Differential diagnostic opportunities for adenosine deaminase testing in pleural effusion. Klinicheskaya Meditsina, 1995, no. 1, pp. 41-42. (In Russ.)
7. Albrich W.C., Harbart S. Pros and cons of using biomarkers versus clinical decisions in start and stop decisions for antibiotics in the critical care setting. Int. Care Med., 2015, vol. 41, pp. 1739-1751.
8. Antonioli L., Csóka B., Fornai M. et al. Adenosine and inflammation: what's new on the horizon? Drug Discov. Today, 2014, vol. 19, pp. 1051-1068. doi: 10.1016/j.drudis.2014.02.010.
9. De Groote M.A., Nahid P., Jarlsber L., Johnson J.L., Marc Weiner M., MuzanyiG., Janjic N., Sterling D.G., Ochsner U.A. Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment. PLoS One, 2013, vol. 8, pp.e61002. doi: 10.1371/journal.pone.0061002.
10. Faas M.M., Sáez T., de Vos P. Extracellular ATP and adenosine: The Yin and Yang in immune responses? Molec. Aspects Med., 2017, vol. 57, pp. 30. doi.org/10.1016/j.mam.2017.01.002.
11. Fredholm B.B. Adenosine, an endogenous distress signal, modulates tissue damage and repair. Cell Death Differentiat., 2007, vol. 14, pp. 1315–1323. doi: 10.1038/sj.cdd.4402132.
12. Giusti G. Adenosine deaminase. Methods of enzymatic analysis. Ed.H.Bergmeyer. New York, Academic Press, 1974, vol. 2, pp. 1092-1099.
13. Hochepied T., Berger F., Baumann H., Libert S. Alpha-1-acid glycoprotein: anacute phase protein with inflammatory and immunomodulating properties. Cytokine Growth Factor Rev., 2003, vol. 14, no. 1, pp. 25-34.
14. Karmouty-Quintana H., Xia Y., Blackburn M.R. Adenosine signaling during acute and chronic disease states. J. Mol. Med., 2013, vol. 91, no. 2, pp. 173-181. doi: 10.1007/s00109-013-0997-1.
15. Liu Q.Y., Han F., Pan L.P., Jia H.Y., Li Q.I., Zhang Z.D. Inflammation responses in patients with pulmonary tuberculosis in an intensive care unit. Exp. Ther. Med., 2018, vol. 15, no. 3, pp. 2719-2726. doi: 10.3892/etm.2018.5775.
16. Pandey R., Tamrakar D., Jaiswal S., Sharma A., Koju S., Duwal S.R., Sharma I., Jayaswal R.P., Pankaj P.P. Serum adenosine deaminase: a novel biomarker tool for the diagnosis of tuberculosis. Biosci. Biotech. Res. Asia, 2016, vol. 13, no. 1, pp. 551-556. doi: 10.13005/bbra/2068.
17. Reichelt M.E., Ashton K.J., Tan X.L., Mustafa S.J., Ledent C., Delbridge L.M.D., Hofmann P.A., Headrick J.P., Morrison R.R. The adenosine A2A receptor ‒ myocardial protectant and coronary target in endotoxemia. Int. J. Cardiol., 2013, vol. 166, no. 3, pp. 672-680. doi: 10.1016/j.ijcard.2011.11.075.
18. Sadrzadeh S.M.H., Bozorgmehr J. Haptoglobin phenotypes in health and disorders. Am. J. Clin. Pathol., 2004, vol. 121, pp. 97-104. doi: 10.1309/8GLX5798Y5XH-0VW.
19. Sathekge M.M., Ankrah A.O., Lawal I., Vorster M. Response to therapy. Semin. Nucl. Med., 2018, vol. 48, no. 2, pp. 166-181. doi: 10.1053/j.semnuclmed.2017.10.004.
20. Thiel M., Chouker A., Ohta A., Jackson E., Caldwell C., Smith P., LukashevD., Bittmann I., Sitkovsky M.V. Oxygenation inhibits the physiological tissue-protecting mechanism and thereby exacerbates acute inflammatory lung injury. PLoS Biol., 2005, vol. 3, no. 6, pp. 1088-1100. doi: 10.1371/journal.pbio.0030174.
21. Weiner L., Kaufmann S.H.E. High-throughput and computational approaches for diagnostic and prognostic host tuberculosis biomarkers. Int. J. Infect. Dis., 2017, vol. 56, pp. 258-262. doi:10.1016/j.ijid.2016.10.017.
Review
For citations:
Dyakova M.E., Аlekseeva N.P., Esmedlyaeva D.S., Yablonskiy P.K. The possibility of predicting effectiveness oftherapy in patients with new infiltrative pulmonary tuberculosis by baseline activity of adenosine deaminase and inflammatory response parameters. Tuberculosis and Lung Diseases. 2022;100(5):28-34. (In Russ.) https://doi.org/10.21292/2075-1230-2022-100-5-28-34
Views:
342
Email this article 